{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016046","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.724784+00:00","generated_at":"2026-06-24T02:08:52.143827+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vir Q2 net loss $76.5M; revenue negative on $397.4M non-cash charge; >$2.6B cash","bullets":["Net loss of $76.5M ($0.58 per share) vs net income of $61.8M ($0.48) in Q2 2021.","Total revenue negative ($40.6M) due to $397.4M non-cash charge for excess sotrovimab supply and manufacturing capacity.","Collaboration revenue from GSK was ($54.9M); $342.5M profit-share expected in Q3 2022.","Cash, equivalents, investments and profit-share payments exceed $2.6B, expected to fund operations for up to five years.","HERBERT 'SKIP' VIRGIN, CSO, stepping down Aug 30; CMO Phil Pang to lead R&D on interim basis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016046","json":"https://secwatch.observer/filing/0000950170-22-016046.json","markdown":"https://secwatch.observer/filing/0000950170-22-016046.md","text":"https://secwatch.observer/filing/0000950170-22-016046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000095017022016046/0000950170-22-016046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000095017022016046/vir-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:08:52.143827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}